Galderma inaugurated its U.S. and Latin America headquarters in Miami on Aug. 24, 2026, establishing a strategic operational center in one of the company’s largest markets. The move consolidates key leadership functions and commercial teams under one roof, with plans to employ approximately 200 staff in the city over time.
The Miami facility will serve as the primary base for U.S. commercial roles in Dermatological Skincare and selected functional teams, while also hosting healthcare professionals. The headquarters includes a dedicated injection room for hands-on training, educational programs, and the development of training materials. An installation modeled on the ALASTIN Signature Practice experience provides visiting professionals with a firsthand look at integrating regenerative, peri-procedural skincare into patient care.
Galderma has hosted more than 1,000 Galderma Aesthetic Injector Network training events in the U.S. in 2026 to date, serving around 5,000 participants. The company cited Miami’s position as a premium market for dermatological skincare and aesthetics, along with its deep talent pool and robust connectivity across the U.S. and Latin America, as key factors in the location choice.
The opening aligns with Galderma’s broader U.S. growth strategy, which includes a previously announced commitment to invest more than $650 million in U.S. manufacturing through 2030. The company reported net sales of $3.134 billion in the first half of 2026, a 24.6% year-on-year increase at constant currency. Global net sales reached $5.207 billion in 2025, reflecting momentum across its science-based portfolio spanning Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology.
The Miami headquarters was designed to foster collaboration, creativity, and employee wellbeing, drawing inspiration from Japandi design principles. The space reflects Galderma’s focus on purposeful innovation and scientific excellence, bringing together U.S. and Latin American leadership teams to enhance operational agility and strategy execution.
